Ads
related to: viral entry inhibitors- Treatment Costs & Savings
See If You Are Eligible For Savings
Or Assistance Programs.
- Long-Acting HIV Treatment
Injections Just Every Other Month
With A Flexible Treatment Window.
- Helpful Patient Tools
Find Information For Patients Here.
Visit The Official Patient Website.
- HIV Treatment Injectable
Learn About A Treatment Option
And Find More Info Online Today.
- Get Treatment Resources
See Tools Specifically For Patients
About Dosing, Savings And More.
- Helpful Resources
Learn About An HIV Treatment
And Discover More About Dosing.
- Treatment Costs & Savings
Search results
Results From The WOW.Com Content Network
Entry inhibitors, also known as fusion inhibitors, are a class of antiviral drugs that prevent a virus from entering a cell, for example, by blocking a receptor. Entry inhibitors are used to treat conditions such as HIV and hepatitis D .
Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. [1] Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding [2] and infection [3] of viral strains which use the CCR5 receptor to infect cells.
Fostemsavir (BMS-663068) is a methyl phosphate prodrug of the small molecule inhibitor BMS-626529, which prevents viral entry by binding to the viral envelope gp120 and interfering with virus attachment to the host CD4 receptor. [22]
Pyrophosphate analogue DNA polymerase inhibitor: 1991 Ganciclovir (Cytovene) [9] Cytomegalovirus (CMV) [10] Competitive nucleoside analogue dGTP inhibitor 1988 Ibacitabine: Herpes labialis: Ibalizumab (Trogarzo) [11] HIV Entry inhibitor 2018 Idoxuridine: Herpes: dU analogue inhibitor 1962 Imiquimod: Genital wart, Basal cell carcinoma, Actinic ...
At least one of these entry inhibitors—a biomimetic peptide called Enfuvirtide, or the brand name Fuzeon—has received FDA approval and has been in use for some time. Potentially, one of the benefits from the use of an effective entry-blocking or entry-inhibiting agent is that it potentially may not only prevent the spread of the virus ...
Entry inhibitors (or fusion inhibitors) interfere with binding, fusion and entry of HIV-1 to the host cell by blocking one of several targets. Maraviroc, enfuvirtide and Ibalizumab are available agents in this class. Maraviroc works by targeting CCR5, a co-receptor located on human helper T-cells.
Ads
related to: viral entry inhibitors